Ensysce's Q2 Loss Widens, but Cy Biopharma Deal Extends Cash Runway to Late 2027

summarizeSummary

Ensysce reported a Q2 net loss of $2.6 million and detailed the Cy Biopharma acquisition that brought in $38.6 million, extending cash runway into late 2027. CY200, the new lead asset for CRPS, has FDA Orphan Drug Designation.

check_boxKey Events · Earnings and Guidance · ENSC

• Q2 Net Loss Widens

  Net loss attributable to common stockholders was $2.6 million ($0.20 per share) for Q2 2026, compared to $1.7 million ($0.79 per share) in Q2 2025, driven by higher R&D spending on PF614.

• Cash Runway Extended

  Following the Cy Biopharma acquisition and $38.6 million PIPE, cash runway extends into late 2027. A second tranche of up to $38.6 million, triggered by clinical milestones, could carry the company into 2028.

• CY200 Orphan Drug Designation

  CY200, the new lead asset for Complex Regional Pain Syndrome (CRPS) Type 1, has received FDA Orphan Drug Designation. There is currently no approved therapy for CRPS.

• PF614-MPAR Progress

  Enrollment continues in the PF614-MPAR-102 study, supported by a NIDA grant with $5.3 million remaining through May 2027. A Taiwan patent extended MPAR protection through 2042.

auto_awesomeAnalysis · ENSC · Life Sciences

The Q2 results confirm a wider net loss of $2.6 million, yet the more consequential development is the post-quarter acquisition of Cy Biopharma and the $38.6 million PIPE that extended cash runway into late 2027. With CY200 now holding FDA Orphan Drug Designation for CRPS and a second financing tranche of up to $38.6 million tied to clinical milestones, the company's near-term survival outlook has transformed. Dilution from the financing and ongoing Nasdaq delisting risk remain key concerns.